These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26909306)

  • 1. Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism.
    Correia JC; Massart J; de Boer JF; Porsmyr-Palmertz M; Martínez-Redondo V; Agudelo LZ; Sinha I; Meierhofer D; Ribeiro V; Björnholm M; Sauer S; Dahlman-Wright K; Zierath JR; Groen AK; Ruas JL
    Mol Metab; 2015 Dec; 4(12):891-902. PubMed ID: 26909306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FXR Isoforms Control Different Metabolic Functions in Liver Cells via Binding to Specific DNA Motifs.
    Ramos Pittol JM; Milona A; Morris I; Willemsen ECL; van der Veen SW; Kalkhoven E; van Mil SWC
    Gastroenterology; 2020 Nov; 159(5):1853-1865.e10. PubMed ID: 32712104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic insights into isoform-dependent and species-specific regulation of bile salt export pump by farnesoid X receptor.
    Song X; Chen Y; Valanejad L; Kaimal R; Yan B; Stoner M; Deng R
    J Lipid Res; 2013 Nov; 54(11):3030-44. PubMed ID: 24002920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic farnesoid X-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in mice.
    Boesjes M; Bloks VW; Hageman J; Bos T; van Dijk TH; Havinga R; Wolters H; Jonker JW; Kuipers F; Groen AK
    PLoS One; 2014; 9(12):e115028. PubMed ID: 25506828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation.
    Zhang Y; Kast-Woelbern HR; Edwards PA
    J Biol Chem; 2003 Jan; 278(1):104-10. PubMed ID: 12393883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of novel splice variants of human farnesoid X receptor.
    Mustonen EK; Lee SML; Nieß H; Schwab M; Pantsar T; Burk O
    Arch Biochem Biophys; 2021 Jul; 705():108893. PubMed ID: 33930378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
    Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
    Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesoid X receptor regulates PI
    Xu J; Yao X; Li X; Xie S; Chi S; Zhang S; Cao J; Tan B
    Fish Physiol Biochem; 2022 Dec; 48(6):1521-1538. PubMed ID: 36210393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ι-Carrageenan Tetrasaccharide Alleviates Liver Lipid Accumulation via the Bile Acid-FXR-SHP/PXR Pathway to Regulate Cholesterol Conversion and Fatty Acid Metabolism in Insulin-Resistant Mice.
    Li Y; Tian Y; Cai W; Wang Q; Chang Y; Sun Y; Dong P; Wang J
    J Agric Food Chem; 2021 Sep; 69(34):9813-9821. PubMed ID: 34415766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis.
    Ploton M; Mazuy C; Gheeraert C; Dubois V; Berthier A; Dubois-Chevalier J; Maréchal X; Bantubungi K; Diemer H; Cianférani S; Strub JM; Helleboid-Chapman A; Eeckhoute J; Staels B; Lefebvre P
    J Hepatol; 2018 Nov; 69(5):1099-1109. PubMed ID: 29981427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
    Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
    Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice.
    Kim KH; Choi S; Zhou Y; Kim EY; Lee JM; Saha PK; Anakk S; Moore DD
    Hepatology; 2017 Aug; 66(2):498-509. PubMed ID: 28378930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism.
    Zhang L; Xie C; Nichols RG; Chan SH; Jiang C; Hao R; Smith PB; Cai J; Simons MN; Hatzakis E; Maranas CD; Gonzalez FJ; Patterson AD
    mSystems; 2016; 1(5):. PubMed ID: 27822554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.
    Yang ZX; Shen W; Sun H
    Hepatol Int; 2010 Aug; 4(4):741-8. PubMed ID: 21286345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition.
    Duran-Sandoval D; Cariou B; Percevault F; Hennuyer N; Grefhorst A; van Dijk TH; Gonzalez FJ; Fruchart JC; Kuipers F; Staels B
    J Biol Chem; 2005 Aug; 280(33):29971-9. PubMed ID: 15899888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
    Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
    Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease.
    Kim SG; Kim BK; Kim K; Fang S
    Endocrinol Metab (Seoul); 2016 Dec; 31(4):500-504. PubMed ID: 28029021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
    Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
    Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.